Effect of metformin on insulin receptor binding and glycaemic control in type II diabetes
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To investigate the effect of metformin on insulin receptor binding and diabetic control, eight obese type II diabetic patients were studied before treatment, after one and four weeks of taking metformin (500 mg thrice daily), and four weeks after withdrawal of the drug. After one and four weeks of treatment the number of erythrocyte insulin receptors had increased by 116% and 184% respectively. This was due almost entirely to an increase in the number of low affinity binding sites. The number of receptors was still raised four weeks after metformin had been withdrawn. Diabetic control as assessed by urinary glucose, glycosylated haemoglobin (HbA5), and glucose tolerance values was significantly improved during metformin treatment, while plasma insulin concentrations were not altered. These results indicate that metformin produces a rapid and protracted increase in low affinity insulin receptors in type II diabetes, associated with greater insulin sensitivity and improved diabetic control.
Introduction
Metformin has a place in the treatment of type II diabetic patients with normal hepatic and renal function. response to diet and in non-obese patients in whom a combination of diet and sulphonylurea has failed to produce glycaemic control.
Metformin reduces hyperglycaemia by increasing peripheral glucose uptake and reducing hepatic gluconeogenesis. The effect of the drug is achieved without an increase in plasma insulin concentrations, suggesting that it potentiates the action of insulin.' The first step in the cellular mechanism of insulin action is the binding of insulin to receptors in the plasma membrane. Metformin reportedly increases insulin binding to receptors in erythrocytes of normal subjects2 and to receptors in cultured lymphocytes and cultured breast cancer cells. 3 
